Overall, our high-throughput drug panel established that RAMS11 expression impacted cellular sensitivity to topoisomerase inhibitors, specifically inhibitors targeting TOP2α, which led to the discovery that RAMS11 overexpression increased TOP2α protein expression in colon cancer cell lines. Here, TOP2A is linked to colonic neoplasm.